MA37872A1 - Sels de composé benzothiazolone utilisés en tant qu'agoniste de beta-2-adrenoceptor - Google Patents
Sels de composé benzothiazolone utilisés en tant qu'agoniste de beta-2-adrenoceptorInfo
- Publication number
- MA37872A1 MA37872A1 MA37872A MA37872A MA37872A1 MA 37872 A1 MA37872 A1 MA 37872A1 MA 37872 A MA37872 A MA 37872A MA 37872 A MA37872 A MA 37872A MA 37872 A1 MA37872 A1 MA 37872A1
- Authority
- MA
- Morocco
- Prior art keywords
- beta
- salts used
- adrenoceptor agonist
- compound salts
- benzothiazolone compound
- Prior art date
Links
- -1 Benzothiazolone compound salts Chemical class 0.000 title 1
- 239000000048 adrenergic agonist Substances 0.000 title 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 title 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 159000000021 acetate salts Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne un composé de formule (i) sous forme de sel acétate (i), un procédé de fabrication du composé de l'invention et ses utilisations thérapeutiques. La présente invention concerne de plus une combinaison de principes pharmacologiquement actifs et des compositions pharmaceutiques.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IQ23912 | 2012-08-30 | ||
| PCT/IB2013/058109 WO2014033654A1 (fr) | 2012-08-30 | 2013-08-29 | Sels de composé benzothiazolone utilisés en tant qu'agoniste de beta-2-adrenoceptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA37872A1 true MA37872A1 (fr) | 2018-07-31 |
Family
ID=53386469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37872A MA37872A1 (fr) | 2012-08-30 | 2013-08-29 | Sels de composé benzothiazolone utilisés en tant qu'agoniste de beta-2-adrenoceptor |
Country Status (26)
| Country | Link |
|---|---|
| EP (2) | EP3243817A1 (fr) |
| KR (1) | KR20150047586A (fr) |
| CN (2) | CN104736525B (fr) |
| BR (1) | BR112015004127A2 (fr) |
| CA (1) | CA2882877A1 (fr) |
| CL (1) | CL2015000461A1 (fr) |
| CY (1) | CY1120225T1 (fr) |
| DK (1) | DK2890687T3 (fr) |
| EA (1) | EA029946B1 (fr) |
| ES (1) | ES2642003T3 (fr) |
| HR (1) | HRP20171362T1 (fr) |
| HU (1) | HUE033655T2 (fr) |
| IL (1) | IL237382A0 (fr) |
| LT (1) | LT2890687T (fr) |
| MA (1) | MA37872A1 (fr) |
| MX (1) | MX351741B (fr) |
| MY (1) | MY169038A (fr) |
| NZ (1) | NZ705319A (fr) |
| PE (1) | PE20150465A1 (fr) |
| PL (1) | PL2890687T3 (fr) |
| PT (1) | PT2890687T (fr) |
| SA (1) | SA515360076B1 (fr) |
| SG (2) | SG11201501293PA (fr) |
| SI (1) | SI2890687T1 (fr) |
| TN (1) | TN2015000058A1 (fr) |
| WO (1) | WO2014033654A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (fr) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Compositions pharmaceutiques a base d'un co-cristal |
| AR040962A1 (es) | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| WO2005110990A1 (fr) | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Heterocycles benzocondenses substitues par hydroxy utilises comme beta-agonistes pour le traitement de maladies respiratoires |
| GB0426164D0 (en) * | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| JO3192B1 (ar) * | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
| WO2014132205A1 (fr) * | 2013-02-28 | 2014-09-04 | Novartis Ag | Préparation contenant un composé de benzothiazolone |
-
2013
- 2013-08-29 SI SI201330750T patent/SI2890687T1/sl unknown
- 2013-08-29 SG SG11201501293PA patent/SG11201501293PA/en unknown
- 2013-08-29 LT LTEP13812075.3T patent/LT2890687T/lt unknown
- 2013-08-29 PL PL13812075T patent/PL2890687T3/pl unknown
- 2013-08-29 MX MX2015002656A patent/MX351741B/es active IP Right Grant
- 2013-08-29 DK DK13812075.3T patent/DK2890687T3/en active
- 2013-08-29 MA MA37872A patent/MA37872A1/fr unknown
- 2013-08-29 HU HUE13812075A patent/HUE033655T2/en unknown
- 2013-08-29 MY MYPI2015000453A patent/MY169038A/en unknown
- 2013-08-29 CN CN201380055093.1A patent/CN104736525B/zh not_active Expired - Fee Related
- 2013-08-29 EA EA201590452A patent/EA029946B1/ru not_active IP Right Cessation
- 2013-08-29 EP EP17171708.5A patent/EP3243817A1/fr not_active Withdrawn
- 2013-08-29 ES ES13812075.3T patent/ES2642003T3/es active Active
- 2013-08-29 SG SG10201704377PA patent/SG10201704377PA/en unknown
- 2013-08-29 PE PE2015000275A patent/PE20150465A1/es not_active Application Discontinuation
- 2013-08-29 CA CA2882877A patent/CA2882877A1/fr not_active Abandoned
- 2013-08-29 EP EP13812075.3A patent/EP2890687B1/fr active Active
- 2013-08-29 WO PCT/IB2013/058109 patent/WO2014033654A1/fr not_active Ceased
- 2013-08-29 NZ NZ705319A patent/NZ705319A/en not_active IP Right Cessation
- 2013-08-29 BR BR112015004127A patent/BR112015004127A2/pt not_active Application Discontinuation
- 2013-08-29 PT PT138120753T patent/PT2890687T/pt unknown
- 2013-08-29 HR HRP20171362TT patent/HRP20171362T1/hr unknown
- 2013-08-29 KR KR1020157007573A patent/KR20150047586A/ko not_active Withdrawn
- 2013-08-29 CN CN201610537241.9A patent/CN106146428A/zh active Pending
-
2015
- 2015-02-20 TN TNP2015000058A patent/TN2015000058A1/fr unknown
- 2015-02-23 IL IL237382A patent/IL237382A0/en unknown
- 2015-02-25 CL CL2015000461A patent/CL2015000461A1/es unknown
- 2015-02-26 SA SA515360076A patent/SA515360076B1/ar unknown
-
2017
- 2017-09-13 CY CY20171100967T patent/CY1120225T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL237382A0 (en) | 2015-04-30 |
| EA201590452A1 (ru) | 2015-07-30 |
| EP3243817A1 (fr) | 2017-11-15 |
| PL2890687T3 (pl) | 2017-11-30 |
| TN2015000058A1 (en) | 2016-06-29 |
| NZ705319A (en) | 2018-05-25 |
| EA029946B1 (ru) | 2018-06-29 |
| LT2890687T (lt) | 2017-09-11 |
| PE20150465A1 (es) | 2015-04-22 |
| HRP20171362T1 (hr) | 2017-11-03 |
| CN104736525A (zh) | 2015-06-24 |
| CN104736525B (zh) | 2016-08-24 |
| HK1206015A1 (en) | 2015-12-31 |
| WO2014033654A1 (fr) | 2014-03-06 |
| DK2890687T3 (en) | 2017-10-09 |
| MY169038A (en) | 2019-02-07 |
| ES2642003T3 (es) | 2017-11-14 |
| SA515360076B1 (ar) | 2016-03-20 |
| CL2015000461A1 (es) | 2015-05-04 |
| EP2890687B1 (fr) | 2017-06-28 |
| PT2890687T (pt) | 2017-10-05 |
| BR112015004127A2 (pt) | 2017-07-04 |
| CA2882877A1 (fr) | 2014-03-06 |
| SI2890687T1 (sl) | 2017-10-30 |
| MX2015002656A (es) | 2015-05-20 |
| KR20150047586A (ko) | 2015-05-04 |
| SG11201501293PA (en) | 2015-03-30 |
| MX351741B (es) | 2017-10-26 |
| CN106146428A (zh) | 2016-11-23 |
| EP2890687A1 (fr) | 2015-07-08 |
| SG10201704377PA (en) | 2017-06-29 |
| CY1120225T1 (el) | 2018-12-12 |
| HUE033655T2 (en) | 2017-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124882T1 (el) | Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn | |
| MA37477A1 (fr) | Modulateurs des voies du complément et leurs utilisations | |
| MA34837B1 (fr) | Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla) | |
| MA37405A1 (fr) | Composés hétérocyclyle | |
| MA35275B1 (fr) | Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a | |
| MA33364B1 (fr) | Dérivés aminobutyriques substitués en tant qu'inhibiteurs de néprilysine | |
| EA201592255A1 (ru) | Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания | |
| EA201592256A1 (ru) | Производные имидазопирролидинона и их применение при лечении заболеваний | |
| MA35032B1 (fr) | Derives de glycoside et leurs utilisations dans le traitement du diabete | |
| MA33886B1 (fr) | Dérivés substitués d'acide carbamoylméthylamino-acétique utilisés comme nouveaux inhibiteurs de nep | |
| MA38330A1 (fr) | Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre) | |
| MA39983B1 (fr) | Dérivés de carboxamide | |
| MX389600B (es) | Nueva composición terapéutica que contiene ingrediente activo de apomorfinas. | |
| MA38865A1 (fr) | Formulation comprenant un agent hypolipidémiant | |
| EA201391524A1 (ru) | Производные гликозида и их применение | |
| UA103329C2 (ru) | Соли соединений-ингибиторов вич | |
| MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 | |
| IN2014DN05972A (fr) | ||
| EA201490573A1 (ru) | Соединение бензотиазолона | |
| EA201591487A1 (ru) | Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью | |
| IN2014MN02433A (fr) | ||
| MA37879B1 (fr) | Forme amorphe stabilisée d'agomélatine, procédé pour sa préparation et compositions pharmaceutiques la contenant | |
| MA34462B1 (fr) | Composes de thiophene 2,3,5- trisubstitues et leurs utilisations | |
| EA201590452A1 (ru) | СОЛИ СОЕДИНЕНИЯ БЕНЗОТИАЗОЛОНА В КАЧЕСТВЕ АГОНИСТОВ β-2-АДРЕНОРЕЦЕПТОРОВ | |
| MA38838B1 (fr) | Dérivés de pipéridinyl-indole et leur utilisation en tant qu'inhibiteurs du facteur b du complément |